Lipella Pharmaceuticals Inc. developed therapies using liposomal drug delivery technology and advanced multiple drug candidates into clinical trials, including Phase 2 studies in hemorrhagic cystitis and oral lichen planus.
In June 2026, Lipella's clinical development programs, intellectual property, and regulatory assets were acquired through Chapter 11 proceedings for continued development.
Disclosure Statement and Plan — Filed September 21, 2026
Revisions were discussed at the October 13 hearing. An updated version will be posted when available.
October 13, 2026 — Court Order
© 2026 Lipella Pharmaceuticals Inc.